A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria for open-label access to ATC because of virologic failure/lack of response.

Registry ID

EUCTR2008-001486-28

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Avexa Limited

Start date

2008-05-14

Completion date

2009-03-13

Last update

2026-08-16

Conditions

• HIV-1

Summary

• To investigate the long-term safety and tolerability of ATC in treatment-experienced HIV-1 infected patients.

Locations

• , , Germany
• , , UK
• , , Belgium
• , , France

Related clinical trials

• Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
• Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
• CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
• Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
• Viral Infection of HSPC Impacts Hematopoiesis

View on source registry